TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31420052

Group type: EXPERIMENTAL
Intervention: Passive leg raising (ΔCRT-PLR)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Volume expansion
Number of subjects: 34
Study: 31420056

Group type: EXPERIMENTAL
Intervention: Physicians' predictions upon ICU admission
Number of subjects: 252

Group type: COMPARATOR
Intervention: AKIpredictor upon ICU admission
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Physicians' predictions on the first morning
Number of subjects: 252

Group type: COMPARATOR
Intervention: AKIpredictor on the first morning
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Physicians' predictions after 24 hours
Number of subjects: 252

Group type: COMPARATOR
Intervention: AKIpredictor after 24 hours
Number of subjects: 252
Study: 31420317

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (bodyweight-adjusted 20 mg-equivalent dose) administered orally; dosing regimens: once-daily for ages 6-17 years, twice-daily for ages 6 months to 11 years, three times-daily for ages younger than 6 months; duration of treatment: 30 days (or 7 days for those younger than 6 months).
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Rivaroxaban (bodyweight-adjusted)
Number of subjects: 93
Study: 31420358

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg every 2 weeks
Number of subjects: 75
Study: 31420379

Group type: EXPERIMENTAL
Intervention: Ultra-low dose (ULD) chest CT using ASiR-V
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard low-dose (LD) CT
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: ULD CT with 50% and 100% ASiR-V
Number of subjects: 150

Group type: COMPARATOR
Intervention: LD CT with 50% ASiR-V
Number of subjects: 150
Study: 31420387

Group type: EXPERIMENTAL
Intervention: End-ischaemic DHOPE followed by COR and NMP
Number of subjects: 0
Study: 31420462

Group type: EXPERIMENTAL
Intervention: Hematoma surface
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hematoma volume
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Peak perihemorrhagic edema
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Edema-modifying therapies
Number of subjects: 300
Study: 31420846

Group type: EXPERIMENTAL
Intervention: Nusinersen
Number of subjects: 323

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 323
Study: 31420849

Group type: EXPERIMENTAL
Intervention: Erbium-YAG laser (6 sessions over 6 months)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (12 sessions over 6 months)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined treatment (Erbium-YAG laser plus Platelet-rich plasma, 6 sessions of laser and 12 sessions of plasma over 6 months)
Number of subjects: 75
Study: 31421008

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: King's College Criteria (KCC) with declining AFP levels
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gc globulin
Number of subjects: 70
Study: 31421023

Group type: EXPERIMENTAL
Intervention: Gray-scale synovitis severity (grade 2-3)
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Power Doppler activity
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Power Doppler activity in CMC1
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Inflammation in CMC1 joints
Number of subjects: 290
Study: 31421111

Group type: EXPERIMENTAL
Intervention: Procedural Sedation (PS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 30
Study: 31421324

Group type: EXPERIMENTAL
Intervention: Depressive symptoms and anxiety (measured by Beck Depression Inventory BDI and Hospital Anxiety and Depression Scale HADS)
Number of subjects: 524

Group type: EXPERIMENTAL
Intervention: Depressive symptoms and anxiety
Number of subjects: 524
Study: 31421471

Group type: EXPERIMENTAL
Intervention: Fluorescently labeled anti-EGFR antibody (panitumumab-IRDye800CW)
Number of subjects: 11
Study: 31421641

Group type: EXPERIMENTAL
Intervention: Embolic stroke of undetermined source (ESUS) patients
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 90
Study: 31421657

Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA-11 PET-CT
Number of subjects: 130
Study: 31421933

Group type: EXPERIMENTAL
Intervention: Reduced-dose apixaban 2.5mg BID
Number of subjects: 6306

Group type: COMPARATOR
Intervention: Standard-dose apixaban 5mg BID
Number of subjects: 6306

Group type: EXPERIMENTAL
Intervention: Recommended reduced-dose group
Number of subjects: 6306

Group type: EXPERIMENTAL
Intervention: Non-recommended reduced-dose group
Number of subjects: 6306
Study: 31422088

Group type: EXPERIMENTAL
Intervention: BP-EES (Biodegradable Polymer Everolimus-Eluting Stent)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: DP-EES (Durable Polymer Everolimus-Eluting Stent)
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: BP-EES
Number of subjects: 1041

Group type: COMPARATOR
Intervention: DP-EES
Number of subjects: 1041
Study: 31422126

Group type: EXPERIMENTAL
Intervention: FLT-PET
Number of subjects: 0

Group type: COMPARATOR
Intervention: FDG/Perfusion-PET
Number of subjects: 0
Study: 31422129

Group type: EXPERIMENTAL
Intervention: Contrast ultrasound with intravenous microbubble infusion for 10 min
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ultrasound (US) alone
Number of subjects: 0
Study: 31422137

Group type: EXPERIMENTAL
Intervention: Coronary CTA advanced plaque assessment
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Low noncalcified plaque volume
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: High noncalcified plaque volume
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Coronary CTA assessment
Number of subjects: 544
Study: 31422141

Group type: EXPERIMENTAL
Intervention: CT-FFR
Number of subjects: 314
Study: 31422759

Group type: EXPERIMENTAL
Intervention: Smoking cessation (eventual abstainers)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Continued smoking (continued smokers)
Number of subjects: 188
Study: 31423298

Group type: EXPERIMENTAL
Intervention: Infants fed a modified gut microbiome
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 31425221

Group type: EXPERIMENTAL
Intervention: Labor Epidural Analgesia (LEA)
Number of subjects: 1204

Group type: COMPARATOR
Intervention: No Labor Epidural Analgesia (Control)
Number of subjects: 1204

Group type: EXPERIMENTAL
Intervention: Previous breastfeeding experience
Number of subjects: 1204
Study: 31425273

Group type: EXPERIMENTAL
Intervention: Sepsis-3
Number of subjects: 21191

Group type: COMPARATOR
Intervention: Severe sepsis/septic shock
Number of subjects: 21191

Group type: EXPERIMENTAL
Intervention: Community-acquired infections
Number of subjects: 21191
Study: 31425366

Group type: EXPERIMENTAL
Intervention: Elemental formula
Number of subjects: 0
Study: 31425735

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 0
Study: 31425781

Group type: EXPERIMENTAL
Intervention: Mepolizumab (40 mg for <40 kg or 100 mg for ≥40 kg) administered subcutaneously over 52 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mepolizumab treatment
Number of subjects: 30
Study: 31426671

Group type: EXPERIMENTAL
Intervention: Worksite smoking cessation services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard smoking cessation services)
Number of subjects: 0
Study: 31426771

Group type: EXPERIMENTAL
Intervention: Extensive option (multiple interventions including online menus, health challenges, support in creating a healthy work environment, coaching by health professionals, health screening, flexibility assessment, online resources, social health platform, activity tracking)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limited option (control group, consisting only of completing a questionnaire regarding health status, lifestyle habits, and behaviors)
Number of subjects: 0
Study: 31427096

Group type: EXPERIMENTAL
Intervention: Gastrostomy tube placement (GT), 333 infants (7.3% of ELBW infants), 76% postdischarge.
Number of subjects: 4549

Group type: EXPERIMENTAL
Intervention: Gastrostomy tube placement (GT)
Number of subjects: 4549
Study: 31427205

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily with dose titration every 14 days up to 10 mg twice daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Axitinib (5 mg twice daily with dose titration)
Number of subjects: 40
Study: 31427321

Group type: EXPERIMENTAL
Intervention: GSK's split-virion inactivated quadrivalent influenza vaccine
Number of subjects: 1000
Study: 31428442

Group type: EXPERIMENTAL
Intervention: Customized electronic registry for monitoring men on active surveillance
Number of subjects: 0
Study: 31428443

Group type: EXPERIMENTAL
Intervention: Home-based, moderate-intensity exercise intervention consisting of aerobic and strengthening components for 12 weeks.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Home-based, moderate-intensity exercise intervention.
Number of subjects: 30
Study: 31428515

Group type: EXPERIMENTAL
Intervention: Padi4 deficient mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (wild-type mice)
Number of subjects: 0
Study: 31428530

Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 33

Group type: COMPARATOR
Intervention: Bosutinib
Number of subjects: 33
Study: 31428637

Group type: EXPERIMENTAL
Intervention: Balneophysiotherapeutic procedures (radon water therapy) for 21 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (17 employees of the spa suffering from osteoarthritis)
Number of subjects: 34
Study: 31429027

Group type: EXPERIMENTAL
Intervention: Bavituximab 3 mg/kg weekly and Sorafenib 400 mg twice daily
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bavituximab and Sorafenib combination
Number of subjects: 38
Study: 31429417

Group type: EXPERIMENTAL
Intervention: Pharmacogenomic (PGx) testing results released to primary care physician immediately after results are available
Number of subjects: 52

Group type: COMPARATOR
Intervention: Pharmacogenomic (PGx) testing results released to primary care physician after 3 months
Number of subjects: 52
Study: 31429722

Group type: EXPERIMENTAL
Intervention: Bedaquiline-containing regimens
Number of subjects: 2600

Group type: EXPERIMENTAL
Intervention: Delamanid-containing regimens
Number of subjects: 2600
Study: 31429798

Group type: EXPERIMENTAL
Intervention: 12-week strength/endurance training program (18 sessions)
Number of subjects: 2
Study: 31430294

Group type: EXPERIMENTAL
Intervention: mHealth lifestyle intervention (digital application)
Number of subjects: 50
Study: 31430318

Group type: EXPERIMENTAL
Intervention: Indirect adherence measures (Medication Possession Ratio, Pill Count, Self-Report)
Number of subjects: 375
Study: 31430405

Group type: EXPERIMENTAL
Intervention: Topical digoxin and furosemide gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31431116

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus in HFrEF
Number of subjects: 6167

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus in HFpEF
Number of subjects: 6167

Group type: COMPARATOR
Intervention: No diabetes mellitus
Number of subjects: 6167
Study: 31431117

Group type: EXPERIMENTAL
Intervention: In-hospital care for heart failure
Number of subjects: 10004

Group type: EXPERIMENTAL
Intervention: Utilization of diagnostic tests
Number of subjects: 10004

Group type: EXPERIMENTAL
Intervention: Prescription rates of guideline-recommended medications
Number of subjects: 10004

Group type: EXPERIMENTAL
Intervention: Follow-up appointments
Number of subjects: 10004

Group type: EXPERIMENTAL
Intervention: Utilization of traditional Chinese medicine
Number of subjects: 10004
Study: 31431387

Group type: EXPERIMENTAL
Intervention: SBRT of the primary tumor
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: FRT to the lymph nodes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SBRT and FRT combined
Number of subjects: 10
Study: 31431673

Group type: EXPERIMENTAL
Intervention: GFRA1 methylation-positive patients
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: ZNF382 methylation-positive patients
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: High-risk GC patients (based on GFRA1 and ZNF382 methylation)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: High-risk GC patients
Number of subjects: 198
Study: 31431932

Group type: EXPERIMENTAL
Intervention: Revised Protein Sparing Modified Fast (rPSMF)
Number of subjects: 0
Study: 31431956

Group type: EXPERIMENTAL
Intervention: Illness perceptions in SLE patients
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Illness perceptions in SSc patients
Number of subjects: 241
Study: 31431998

Group type: EXPERIMENTAL
Intervention: TCZ-SC 162 mg once weekly for 52 weeks (monotherapy)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: TCZ-SC 162 mg once weekly for 52 weeks (combination therapy with csDMARDs)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: TCZ-SC (both monotherapy and combination therapy)
Number of subjects: 161
Study: 31432451

Group type: EXPERIMENTAL
Intervention: Under-dosing of rivaroxaban (less than 15 mg once daily)
Number of subjects: 6521
Study: 31433059

Group type: EXPERIMENTAL
Intervention: CSE (1000mg ceftriaxone/500mg sulbactam/37mg disodium EDTA) every 12h
Number of subjects: 230

Group type: COMPARATOR
Intervention: Meropenem (1000mg) every 8h
Number of subjects: 230
Study: 31433472

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 4336
Study: 31433489

Group type: EXPERIMENTAL
Intervention: Point-of-Care Pharmacogenomic Decision Support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31433708

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Number of subjects: 46
Study: 31433768

Group type: EXPERIMENTAL
Intervention: Defining clinical roles and responsibilities
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Hiring staff to perform discharge medication reconciliation
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Training staff to take medication histories
Number of subjects: 791

Group type: EXPERIMENTAL
Intervention: Implementing a new electronic health record (EHR)
Number of subjects: 791
Study: 31433920

Group type: EXPERIMENTAL
Intervention: Oral selinexor (80 mg) plus dexamethasone (20 mg) twice weekly
Number of subjects: 122
Study: 31434508

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 97
Study: 31434543

Group type: EXPERIMENTAL
Intervention: High-intensity stepping (70%-80% heart rate reserve) of variable, difficult stepping tasks (high variable)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-intensity stepping performing only forward walking (high forward)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Low-intensity stepping in variable contexts at 30% to 40% heart rate reserve (low variable)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-variable training
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-intensity training
Number of subjects: 97
Study: 31434769

Group type: EXPERIMENTAL
Intervention: Antibiotic-related knowledge and attitudes in Chiang Rai
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Antibiotic-related knowledge and attitudes in Salavan
Number of subjects: 2141

Group type: EXPERIMENTAL
Intervention: Local expressions for antibiotics in Chiang Rai
Number of subjects: 2141
Study: 31434783

Group type: EXPERIMENTAL
Intervention: Household survey regarding influenza-like illness (ILI) and vaccination during the 2015/2016 season
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis of influenza viruses collected during the 2016/2017 season using whole genome sequencing (WGS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of influenza-specific antibody titres against all vaccinated and circulated strains during the 2016/2017 season
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linking survey data and PCR-confirmed cases to Statistics Office data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phylodynamic analyses of WGS data in the context of patient epidemiological data
Number of subjects: 0
Study: 31434793

Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg per day orally plus another aromatase inhibitor
Number of subjects: 18
Study: 31434940

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy in TNBC (n=239)
Number of subjects: 3520

Group type: EXPERIMENTAL
Intervention: Endocrine treatment in ER+/HER2-/LN- (n=1113)
Number of subjects: 3520

Group type: EXPERIMENTAL
Intervention: Endocrine treatment in ER+/HER2-/LN+ (n=423)
Number of subjects: 3520

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy and endocrine treatment in HER2+/ER+ (n=239)
Number of subjects: 3520

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy and endocrine treatment in ER+/HER2-/LN+ (n=433)
Number of subjects: 3520

Group type: EXPERIMENTAL
Intervention: Endocrine treatment in ER+/HER2-/LN- untreated (n=200)
Number of subjects: 3520

Group type: EXPERIMENTAL
Intervention: TNBC-untreated (n=82)
Number of subjects: 3520

Group type: EXPERIMENTAL
Intervention: HER2+/ER- with anti-HER2+ ACT treatment (n=110)
Number of subjects: 3520

Group type: EXPERIMENTAL
Intervention: HER2+/ER+ with anti-HER2+ ACT + endocrine treatment (n=239)
Number of subjects: 3520
Study: 31435905

Group type: EXPERIMENTAL
Intervention: Aprocitentan
Number of subjects: 16
Study: 31436599

Group type: EXPERIMENTAL
Intervention: Informing participants about their diagnosis of HAND
Number of subjects: 139
Study: 31437454

Group type: EXPERIMENTAL
Intervention: EUS-guided liver biopsy (EUS-LB) sampling using a 22-gauge fork-tip core biopsy needle
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EUS-guided liver biopsy (EUS-LB) sampling
Number of subjects: 41
Study: 31438761

Group type: EXPERIMENTAL
Intervention: Smartphone telemedicine intervention
Number of subjects: 7
Study: 31438885

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cell (BMMC) transplantation
Number of subjects: 25
Study: 31438926

Group type: EXPERIMENTAL
Intervention: Discontinuation Prediction Score (DiPS) using logistic regression and support vector machine methods
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: DiPS scores for resource allocation in physical activity intervention programs
Number of subjects: 210
Study: 31439037

Group type: EXPERIMENTAL
Intervention: MEDI0680 administered intravenously at doses of 0.1, 0.5, 2.5, 10, or 20 mg/kg Q2W or Q3W, with some cohorts receiving 20 mg/kg once a week for 2 or 4 weeks, then 20 mg/kg Q2W for a total treatment duration of 12 months or until progression.
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MEDI0680
Number of subjects: 58
Study: 31439295

Group type: EXPERIMENTAL
Intervention: MRI Ready ICD system
Number of subjects: 220
Study: 31439296

Group type: EXPERIMENTAL
Intervention: Early ventricular arrhythmias (VAs) occurring <30 days post-LVAD implantation
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Patients discharged alive from hospital
Number of subjects: 652
Study: 31439537

Group type: EXPERIMENTAL
Intervention: Carfilzomib at a dose of 20 mg/m²
Number of subjects: 9
Study: 31439586

Group type: EXPERIMENTAL
Intervention: Radical tumor resection
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Detection of ctDNA on the third day after R0 resection
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Minimal residual disease (MRD) detection
Number of subjects: 36
Study: 31439614

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CPM score
Number of subjects: 26
Study: 31439873

Group type: EXPERIMENTAL
Intervention: high-frequency tRNS (100-640 Hz; 2 mA; 20 minutes)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: high-frequency tRNS
Number of subjects: 30

Group type: COMPARATOR
Intervention: rTMS
Number of subjects: 30
Study: 31440186

Group type: EXPERIMENTAL
Intervention: Low-to-moderate exercise program (4 times a week for 5 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intensive exercise program (4 times a week for 5 weeks)
Number of subjects: 23
Study: 31440489

Group type: EXPERIMENTAL
Intervention: Developmental Coach System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31440722

Group type: EXPERIMENTAL
Intervention: Lacosamide (adjunctive therapy)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Lacosamide (adjunctive therapy) in SCB (+) subgroup (n=149)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Lacosamide (adjunctive therapy) in SCB (-) subgroup (n=153)
Number of subjects: 311
Study: 31440853

Group type: EXPERIMENTAL
Intervention: Resuscitation with 0.9% saline
Number of subjects: 434

Group type: COMPARATOR
Intervention: Resuscitation with 3% saline
Number of subjects: 434
Study: 31440945

Group type: EXPERIMENTAL
Intervention: Incidental craniopharyngiomas (incCP)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Symptomatic craniopharyngiomas (symCP)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Comparison of incCP and symCP
Number of subjects: 218
Study: 31440946

Group type: EXPERIMENTAL
Intervention: Pasireotide (subcutaneous)
Number of subjects: 127
Study: 31441351

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 3501

Group type: COMPARATOR
Intervention: No diabetes mellitus
Number of subjects: 3501
Study: 31441881

Group type: EXPERIMENTAL
Intervention: Plasma NGAL in patients with good neurologic outcomes
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Plasma NGAL in survived group
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Plasma NGAL predictive performance for neurologic outcome
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Plasma NGAL correlation with 28-day mortality
Number of subjects: 75
Study: 31442103

Group type: EXPERIMENTAL
Intervention: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib at 120, 160, 200, or 240 mg/d orally
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib at 160 mg/d orally
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: T-DM1 at 3.6 mg/kg intravenously every 3 weeks plus neratinib (various doses)
Number of subjects: 27
Study: 31442277

Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 74
Study: 31442327

Group type: EXPERIMENTAL
Intervention: Radium-223 re-treatment (up to 6 additional injections)
Number of subjects: 44